295 related articles for article (PubMed ID: 11593107)
1. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.
Würzner G; Gerster JC; Chiolero A; Maillard M; Fallab-Stubi CL; Brunner HR; Burnier M
J Hypertens; 2001 Oct; 19(10):1855-60. PubMed ID: 11593107
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout.
Liberopoulos E; Christides D; Elisaf M
J Hypertens; 2002 Feb; 20(2):347. PubMed ID: 11821722
[No Abstract] [Full Text] [Related]
3. Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population.
Dang A; Zhang Y; Liu G; Chen G; Song W; Wang B
J Hum Hypertens; 2006 Jan; 20(1):45-50. PubMed ID: 16281062
[TBL] [Abstract][Full Text] [Related]
4. [The effects of angiotensin II receptor blockers in hypertensive patients complicating hyperuricaemia].
Dang AM; Liu GZ; Zhang YH; Chen GL;
Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Oct; 34(10):882-5. PubMed ID: 17217711
[TBL] [Abstract][Full Text] [Related]
5. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension.
Puig JG; Mateos F; Buño A; Ortega R; Rodriguez F; Dal-Ré R
J Hypertens; 1999 Jul; 17(7):1033-9. PubMed ID: 10419078
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators.
Kassler-Taub K; Littlejohn T; Elliott W; Ruddy T; Adler E
Am J Hypertens; 1998 Apr; 11(4 Pt 1):445-53. PubMed ID: 9607383
[TBL] [Abstract][Full Text] [Related]
7. Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients.
Pechère-Bertschi A; Nussberger J; Decosterd L; Armagnac C; Sissmann J; Bouroudian M; Brunner HR; Burnier M
J Hypertens; 1998 Mar; 16(3):385-93. PubMed ID: 9557932
[TBL] [Abstract][Full Text] [Related]
8. Impact of irbesartan, an angiotensin receptor blocker, on uric acid level and oxidative stress in high-risk hypertension patients.
Chida R; Hisauchi I; Toyoda S; Kikuchi M; Komatsu T; Hori Y; Nakahara S; Sakai Y; Inoue T; Taguchi I
Hypertens Res; 2015 Nov; 38(11):765-9. PubMed ID: 26178150
[TBL] [Abstract][Full Text] [Related]
9. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA.
Schmidt A; Gruber U; Böhmig G; Köller E; Mayer G
Nephrol Dial Transplant; 2001 May; 16(5):1034-7. PubMed ID: 11328912
[TBL] [Abstract][Full Text] [Related]
10. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
Smith DH; Dubiel R; Jones M
Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of the efficacy of angiotensin II receptor blockers for uric acid level change in asymptomatic hyperuricaemia.
Kim HS; Kim H; Lee SH; Kim JH
J Clin Pharm Ther; 2020 Dec; 45(6):1264-1270. PubMed ID: 32737930
[TBL] [Abstract][Full Text] [Related]
12. A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension.
Mimran A; Ruilope L; Kerwin L; Nys M; Owens D; Kassler-Taub K; Osbakken M
J Hum Hypertens; 1998 Mar; 12(3):203-8. PubMed ID: 9579771
[TBL] [Abstract][Full Text] [Related]
13. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.
Croom KF; Curran MP; Goa KL; Perry CM
Drugs; 2004; 64(9):999-1028. PubMed ID: 15101793
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension.
Tikkanen I; Omvik P; Jensen HA
J Hypertens; 1995 Nov; 13(11):1343-51. PubMed ID: 8984133
[TBL] [Abstract][Full Text] [Related]
15. [Irbesartan in hypertensive non-diabetic advanced chronic kidney disease. Comparative study with ACEI].
Coronel F; Cigarrán S; García-Mena M; Herrero JA; Calvo N; Pérez-Flores I
Nefrologia; 2008; 28(1):56-60. PubMed ID: 18336132
[TBL] [Abstract][Full Text] [Related]
16. To study the efficacy of Losartan on urinary uric acid excretion in Thiazide induced hyperuricemic and hypertensive patients.
Khan M; Khan RA; Islam F; Laghari J; Jamali SN
Pak J Pharm Sci; 2011 Oct; 24(4):583-7. PubMed ID: 21959825
[TBL] [Abstract][Full Text] [Related]
17. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease.
Gansevoort RT; de Zeeuw D; Shahinfar S; Redfield A; de Jong PE
J Hypertens Suppl; 1994 Jul; 12(2):S37-42. PubMed ID: 7965264
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertension.
Chiou KR; Chen CH; Ding PY; Chen YT; Ting CT; Huang JL; Chiang AH; Liu CP; Tseng CJ; Chao CT; Chang MS
Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):368-76. PubMed ID: 10862446
[TBL] [Abstract][Full Text] [Related]
20. Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients.
Minghelli G; Seydoux C; Goy JJ; Burnier M
Transplantation; 1998 Jul; 66(2):268-71. PubMed ID: 9701277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
